Table 6. Immune reconstitution rate and hazard ratio in patients with different baseline characteristics.
| Baseline characteristics* | Within first 3 months of the ART | Within first year of the ART | Within end point of the observation | |||
|---|---|---|---|---|---|---|
| Immune† reconstitution | HR‡ CI95 p |
Immune reconstitution | HR‡ CI95 p |
Immune† reconstitution | HR‡ CI95 p |
|
| CD4 count | ||||||
| <200 cell/μL | 0% | 2.8 (1.7–4.7) |
14.6% | 2.1 (1.5–3.0) |
36.6% | 1.9 (1.4–2.4) |
| 200–350 cell/μL | 30.0% | 52.0% | 77.5% | |||
| 351–500 cell/μL | 50.0% | 65.5% | 83.3% | |||
| p value | < 0.001 | < 0.001 | < 0.001 | < 0.001 | < 0.001 | < 0.001 |
| Clinical Stage | ||||||
| Stage 1 | 30.2% | 0.6 (0.4–0.8) |
61.0% | 0.7 (0.5–0.8) |
74.4% | 0.7 (0.6–0.8) |
| Stage II | 37.5% | 50.0% | 87.5% | |||
| Stage III | 35.3% | 58.8% | 76.5% | |||
| Stage IV | 0.0% | 13.5% | 36.8% | |||
| p value | < 0.05 | < 0.005 | > 0.05 | < 0.001 | < 0.05 | < 0.005 |
| Viral Load | ||||||
| High (≥500 000 copies/mL) | 12.5% | 3.0 (0.7–12.7) |
43.7% | 1.3 (0.6–3.0) |
62.5% | 1.2 (0.6–2.4) |
| Low (<500 000 copies/mL) | 37.9% | 55.7% | 69.6% | |||
| p value | < 0.05 | > 0.05 | > 0.05 | > 0.05 | > 0.05 | > 0.05 |
abbreviations: ART, antiretroviral therapy; HR, hazard ratio; CI95, 95% confidential interval
*-only characteristics with significant difference in immune reconstitution rate are presented in the table (Fisher’s exact test, p < 0.05)
†-p values for immune reconstitution rate were calculated using Pearson’s chi-square
-p values for hazard ratio were calculated using Wald test